Chicago、ILにおける膠芽腫の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、膠芽腫に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
被験者募集中第3相
- Northwestern University, Chicago
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
被験者募集中第1/2相
- University of Chicago Comprehensive Cancer Center, Chicago
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
被験者募集中第1相
- Northwestern Univerity, Chicago
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
被験者募集中第1相
- Northwestern University, Chicago
Targeted Pediatric High-Grade Glioma Therapy
被験者募集中観察研究
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
被験者募集中第1相
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Study of Olutasidenib and Temozolomide in HGG
被験者募集中第2相
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
被験者募集中第3相
- University of Chicago, Chicago
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
被験者募集中第1相
- Northwestern Medicine, Chicago
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
被験者募集中第2相
- Northwestern University, Chicago
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
被験者募集中早期第1相健康なボランティア歓迎
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
被験者募集中第2相
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
他の都市における膠芽腫の試験
- New York City, NY30件の研究
- Boston, MA28件の研究
- Houston, TX26件の研究
- Los Angeles, CA24件の研究
- Durham, NC20件の研究
- San Francisco, CA17件の研究
- Washington, DC15件の研究
- Columbus, OH14件の研究
- Miami, FL14件の研究
- Rochester, MN13件の研究
- Jacksonville, FL13件の研究
- Aurora, CO12件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん59件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肺がん41件の研究
- 肥満症41件の研究
- 卵巣がん36件の研究
- 大腸癌34件の研究
- 脳卒中34件の研究
- 心不全31件の研究
- 過体重29件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。